OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Ip on the Utility of Investigational Treatments for COVID-19 in Oncology

March 31st 2021

Andrew Ip, MD, MS, discusses the utility of investigational treatments for COVID-19 in patients with cancer.

Dr. Porter on Potential Sequencing With ADCs and TKIs in HER2+ Lung Cancer

March 31st 2021

Jason Porter, MD, discusses potential sequencing strategies with antibody-drug conjugates and TKIs in HER2-positive lung cancer.

Dr. Bazhenova on the Importance of Testing for HER2 Mutations in Lung Cancer

March 31st 2021

Lyudmila A. Bazhenova, MD, discusses the importance of testing for HER2 mutations in lung cancer.

Dr. Abu-Zeinah on the Efficacy of Interferon-Alpha in Polycythemia Vera

March 30th 2021

Ghaith Abu-Zeinah, MD, discusses the efficacy of interferon-alpha in polycythemia vera.

Dr. Kalinsky on the Potential Role of Ovarian Function Suppression in HR+/HER2- Breast Cancer

March 30th 2021

Kevin Kalinsky, MD, MS, discusses the potential role of ovarian function suppression in hormone receptor–positive, HER2-negative breast cancer.

Dr. Cohen on the Goals of the SPEARHEAD-2 Trial in Head and Neck Cancer

March 30th 2021

Ezra Cohen, MD, FRCPSC, FASCO, discusses the goals of the phase 2 SPEARHEAD-2 trial in head and neck cancer.

Dr. Wenham on Future Directions with Antibody-Drug Conjugates in Ovarian Cancer

March 30th 2021

Robert Wenham, MD, MS, FACOG, FACS, discusses future directions with antibody-drug conjugates in the treatment of patients with ovarian cancer.

Dr. Walters on the Drawbacks of Transfusion Dependence in Pediatric Beta-Thalassemia

March 29th 2021

Mark Walters, MD, discusses the limitations of standard blood transfusions in pediatric patients with transfusion-dependent beta-thalassemia.

Dr. Merchant on the Importance of Continued Care in Pediatric Craniopharyngioma

March 29th 2021

Thomas E. Merchant, DO, PhD, discusses the importance of continued care in pediatric patients with craniopharyngioma.

Dr. Grothey on the Differences Between Available ctDNA Assays in CRC

March 29th 2021

Axel Grothey, MD, discusses the differences between available assays evaluating circulating tumor DNA in colorectal cancer.

Dr. Robinson on the Updated Results of the KEYNOTE-407 Trial in Squamous NSCLC

March 26th 2021

Andrew G. Robinson, MD, MSc, FRCPC, discusses the updated results of the phase 3 KEYNOTE-407 trial in squamous non–small cell lung cancer.

Dr. Bazhenova on a Correlative Analysis of the KRYSTAL-1 Trial in Advanced NSCLC

March 26th 2021

Lyudmila A. Bazhenova, MD, discusses the results of a preliminary exploratory correlative analysis of the phase 1/2 KRYSTAL-1 trial in advanced non–small cell lung cancer.

Dr. Shah on the Potential Rationale for Selecting Ide-Cel Vs Cilta-Cel In Multiple Myeloma

March 26th 2021

Nina Shah, MD, discusses the potential rationale for selecting between the investigational CAR T-cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Dr. Garassino on the Rationale for the PACIFIC-6 Trial in NSCLC

March 25th 2021

Marina Chiara Garassino, MD, discusses the rationale for the phase 2 PACIFIC-6 trial in non–small cell lung cancer.

Dr. Bekaii-Saab on the Challenges of Utilizing Chemotherapy-Free Regimens in CRC

March 25th 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses the challenges of utilizing chemotherapy-free regimens in colorectal cancer.

Dr. del Rio on the Reactogenicity of the COVID-19 Vaccines

March 24th 2021

Carlos del Rio, MD, discusses the reactogenicity of the COVID-19 vaccines.

Dr. Iams on Emerging TKIs and ADCs in HER2-Mutant Lung Cancer

March 24th 2021

Wade T. Iams, MD, discusses the emergence of TKIs and antibody-drug conjugates in HER2-mutant lung cancer.

Dr. Boyle on Approaching Biomarker Testing in Lung Cancer

March 24th 2021

Theresa Boyle, MD, PhD, discusses the current approach to biomarker testing in lung cancer.

Dr. Usmani on Future Research Directions for Nirogacestat/Teclistamab in Myeloma

March 23rd 2021

Saad Z. Usmani, MD, FACP, discusses future research directions with the combination of nirogacestat and teclistamab in patients with relapsed/refractory multiple myeloma.

Dr. Kamat on the Process of Meeting BCG Needs in Bladder Cancer

March 23rd 2021

Ashish M. Kamat, MD, discusses the process of meeting the needs for TICE Bacillus Calmette–Guérin in the treatment of patients with bladder cancer.